British biopharmaceutical company GlaxoSmithKline will lay off 150 employees in its Cambridge operations by the end of March 2026, the company said in a notice to the state. The company said Monday ...

While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...

ESET Research remains at the core of our efforts, informing not only the prevention-enhancing capabilities and R&D of our products (such as ESET Threat Intelligence), but also providing a better ...

Archer’s Midnight aircraft nears production, targeting FAA approval by 2025 for passenger flights. Click here to read my most recent analysis of ACHR.

Advanced Micro-Fabrication Equipment Inc., China (AMEC) has delivered the world's first Primo Menova 12-inch metal etching system to a top domestic IC design and manufacturing service provider ...

To improve firms’ enthusiasm for R&D investment, governments worldwide have implemented a series of tax incentives, such as the Super Tax Deduction policy (STD-policy), and the Preferential Income Tax ...

Sigachi Industries, a Hyderabad-based small-cap pharmaceutical firm, saw a near 2 per cent rise in its share price on 18 June 2025 after unveiling a strategic R&D centre aimed at accelerating API ...

Targeting the GSK-3β pathway through probiotics may provide a promising strategy to lower tau pathology and subsequently treat both AD and DM. In line with what has been shown in AD animal models, ...

GlaxoSmithKline is significantly shrinking activities in Research Triangle Park, N.C., as it shifts most of its R&D operations to sites in Stevenage, England, and Philadelphia. The move is part of a ...